An Innovation Leader in Immuno-Dermatology

Mission

An R&D anchored immuno-dermatology focused company to redefine the treatment landscape, bringing transformative solutions to patients worldwide.

Learn more

Team

Our team of co-founders is comprised of experienced dermatology and scientific experts with a mission to redefine immuno-dermatology.

Learn more

Pipeline

Alys has an R&D pipeline enabled by multi-platform technologies with over a dozen active programs with potential to transform treatment landscape across dermatologic conditions.

Learn more

Latest News

Alys Pharmaceuticals announces CTA submission for ALY-301, the first mast cell selective c-Kit inhibitor for treatment of Cold Urticaria 10 June 2025 - Alys Pharmaceuticals, Inc. (“Alys”), an immune-dermatology focused company, today announces the submission of a Clinical Trial Application (CTA) to Germany’s Paul-Ehrlich-Institut (PEI) to initiate a Phase 1/1b study of ALY-301 in healthy volunteers and patients suffering from Cold Urticaria, a subtype of Chronic Inducible Urticaria (CIndU).

Events

There are currently no upcoming events

An Innovation Leader in Immuno-Dermatology

Mission

Team

Pipeline

Latest News

Events

© Alys Pharmaceuticals, Inc.

Address

Useful links